These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31587298)

  • 41. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts.
    Royer S; Morais AP; da Fonseca Batistão DW
    Arch Microbiol; 2021 May; 203(4):1271-1279. PubMed ID: 33474609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biological challenges of phage therapy and proposed solutions: a literature review.
    Caflisch KM; Suh GA; Patel R
    Expert Rev Anti Infect Ther; 2019 Dec; 17(12):1011-1041. PubMed ID: 31735090
    [No Abstract]   [Full Text] [Related]  

  • 43. Preclinical data and safety assessment of phage therapy in humans.
    Nale JY; Clokie MR
    Curr Opin Biotechnol; 2021 Apr; 68():310-317. PubMed ID: 33862490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model.
    Manohar P; Nachimuthu R; Lopes BS
    BMC Microbiol; 2018 Aug; 18(1):97. PubMed ID: 30170558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing the Timing and Composition of Therapeutic Phage Cocktails: A Control-Theoretic Approach.
    Li G; Leung CY; Wardi Y; Debarbieux L; Weitz JS
    Bull Math Biol; 2020 Jun; 82(6):75. PubMed ID: 32533350
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reassessment of Historical Clinical Trials Supports the Effectiveness of Phage Therapy.
    Marongiu L; Burkard M; Lauer UM; Hoelzle LE; Venturelli S
    Clin Microbiol Rev; 2022 Dec; 35(4):e0006222. PubMed ID: 36069758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biological foundations of successful bacteriophage therapy.
    Venturini C; Petrovic Fabijan A; Fajardo Lubian A; Barbirz S; Iredell J
    EMBO Mol Med; 2022 Jul; 14(7):e12435. PubMed ID: 35620963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phage Therapy in the Postantibiotic Era.
    Gordillo Altamirano FL; Barr JJ
    Clin Microbiol Rev; 2019 Apr; 32(2):. PubMed ID: 30651225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (
    Onsea J; Uyttebroek S; Chen B; Wagemans J; Lood C; Van Gerven L; Spriet I; Devolder D; Debaveye Y; Depypere M; Dupont L; De Munter P; Peetermans WE; van Noort V; Merabishvili M; Pirnay JP; Lavigne R; Metsemakers WJ
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naturally-occurring and cultured bacteriophages in human therapy.
    Kiani AK; Anpilogov K; Dhuli K; Paolacci S; Benedetti S; Manara E; Guerri G; Dautaj A; Beccari T; Dundar M; Bertelli M
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(1 Suppl):101-107. PubMed ID: 34890040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.
    Rohde C; Resch G; Pirnay JP; Blasdel BG; Debarbieux L; Gelman D; Górski A; Hazan R; Huys I; Kakabadze E; Łobocka M; Maestri A; Almeida GMF; Makalatia K; Malik DJ; Mašlaňová I; Merabishvili M; Pantucek R; Rose T; Štveráková D; Van Raemdonck H; Verbeken G; Chanishvili N
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29621199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Phage therapy for respiratory infections].
    Mitropoulou G; Gijs PJ; Koutsokera A; Sauty A; Blanchon S; Csajka C; Brunet JF; Resch G; Guery B; Von Garnier C
    Rev Med Suisse; 2022 Nov; 18(804):2150-2156. PubMed ID: 36382975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases.
    Cesta N; Di Luca M; Corbellino M; Tavio M; Galli M; Andreoni M
    Infez Med; 2020 Sep; 28(3):322-331. PubMed ID: 32920567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phage therapy efficacy: a review of the last 10 years of preclinical studies.
    Melo LDR; Oliveira H; Pires DP; Dabrowska K; Azeredo J
    Crit Rev Microbiol; 2020 Feb; 46(1):78-99. PubMed ID: 32091280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole.
    Abdelkader K; Gerstmans H; Saafan A; Dishisha T; Briers Y
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30678377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ameliorating the antimicrobial resistance crisis: phage therapy.
    Saha D; Mukherjee R
    IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phages Needed against Resistant Bacteria.
    Moelling K
    Viruses; 2020 Jul; 12(7):. PubMed ID: 32664292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biotechnological applications of bacteriophages: State of the art.
    Harada LK; Silva EC; Campos WF; Del Fiol FS; Vila M; Dąbrowska K; Krylov VN; Balcão VM
    Microbiol Res; 2018; 212-213():38-58. PubMed ID: 29853167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Phage therapy, an additional strategy against multidrug-resistant bacteria].
    Boniver M; Wotquenne P; Moutschen M; Rousseau AF
    Rev Med Liege; 2022 Sep; 77(9):510-515. PubMed ID: 36082597
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stability of magistral phage preparations before therapeutic application in patients with chronic rhinosinusitis, sepsis, pulmonary, and musculoskeletal infections.
    Uyttebroek S; Bessems L; Metsemakers W-J; Debaveye Y; Van Gerven L; Dupont L; Depypere M; Wagemans J; Lavigne R; Merabishvili M; Pirnay J-P; Devolder D; Spriet I; Onsea J
    Microbiol Spectr; 2023 Dec; 11(6):e0290723. PubMed ID: 37819122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.